Boston Scientific has temporarily halted enrollment in its AVANT GUARD trial, which is evaluating the FARAPULSE Pulsed Field Ablation (PFA) System for persistent atrial fibrillation (AFib). The pause is due to unanticipated observations in the trial, which is focusing on drug-naive patients, a population not currently indicated for PFA treatment. The company emphasizes that the observations are not life-threatening and that they remain confident in the FARAPULSE system’s overall performance.